GET DAILY SIGNALSStereotaxis (STXS) Drops -17.9% in 30 Days Amid Earnings Miss and Supply Pressures
Key Takeaways
- Stereotaxis (STXS) declined roughly 17.9% over the last 30 days, falling from a closing price of $1.06 on October 13, 2026 to approximately $0.87 as of mid-November 2026.
- The stock's slide reflects a third-quarter earnings miss, weaker-than-expected recurring revenue, and a convertible note financing that underscored the company's need for additional capital.
- Supply constraints for the MAGiC robotic catheter and the ongoing transition away from the legacy Johnson & Johnson (JNJ) ecosystem pressured the recurring revenue segment.
- Positive catalysts, including an expanded FDA clearance for the GenesisX system, a Canon collaboration, and the first U.S. GenesisX installation, have been partially offset by near-term execution concerns.
- Over the trailing quarter, the stock has fallen roughly 38%, reflecting a sustained downtrend despite improving capital-system momentum.
- Investors continue to weigh Stereotaxis' long-term robotics platform potential against persistent cash burn and profitability timeline risks.
- Explore additional pages for more detail on Stereotaxis' Price Targets, Earnings, and Forecast.
- For broader market insight, explore Trending AI Robots.
Company Background and Positioning
Stereotaxis, Inc. stands out as a pioneer in surgical robotics focused on minimally invasive endovascular procedures. The company develops robotic systems, instruments, and digital solutions mainly for cardiac electrophysiology, including catheter ablation. Its Genesis Robotic Magnetic Navigation platform, the newer GenesisX system, and the Synchrony operating-room cockpit anchor the capital equipment side, while disposable catheters drive recurring revenue. The technology has supported treatment of more than 150,000 patients globally. I follow STXS for its role in the growing endovascular robotics space and the shift toward a higher-margin model centered on recurring disposables. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Performance: 30 Days Versus the Quarter
Over the past 30 days, STXS fell about 17.9%, moving from a close of $1.06 on October 13, 2026 to roughly $0.87 in mid-November. The path was uneven, with the shares hovering near $1.00 late in October before a sharp drop early in November, a brief rebound above $1.10, and then another decline following the third-quarter report. The trailing quarter showed a steeper move lower, with the stock off roughly 38% from levels near $1.40 in mid-August. This sustained pressure stems from a mix of earnings shortfalls, balance-sheet questions, and catheter supply issues, even as management highlighted progress on new system placements.
Key Drivers Behind the Last 30 Days
The standout event was the third-quarter 2026 results released on November 10, 2026. Revenue reached $8.9 million, up 20% year over year, yet missed consensus estimates around $9.6 million, while GAAP EPS of -$0.07 came in below the expected -$0.05. Recurring revenue of $5.9 million slipped 4% sequentially, weighed down by production limits on the MAGiC catheter and customers moving away from the legacy Johnson & Johnson ecosystem. The company ended the quarter with about $1.9 million in unfilled disposable orders tied to those supply limits.
At the same time, Stereotaxis announced convertible note financing of up to $24 million, with an initial $12 million drawn and an optional $12 million linked to regulatory milestones. The move bolstered liquidity but spotlighted a cash balance of just $4.0 million at September 30, 2026 and ongoing burn, which weighed on sentiment. The notes carry 10% interest and a $1.21 conversion price. These factors overshadowed positives such as the August FDA clearance for GenesisX with any non-modified X-ray system, the late-October Canon collaboration, and work toward the first U.S. GenesisX installation.
Drivers Over the Trailing Quarter
Across the past three months, STXS dropped roughly 38% as investor sentiment softened. Operational steps forward included initial GenesisX and Synchrony commercialization, the first Genesis sale in China, multi-lab Synchrony adoption at Abbott Northwestern Hospital, and completion of the Robocath acquisition. Still, recurring revenue growth stalled on MAGiC supply shortages, gross margin narrowed to 45% amid low volumes, and adjusted operating expenses rose after the Robocath deal. Softer recurring revenue, a $6.5 million negative cash flow for the quarter, and a shrinking cash position drove the slide despite better capital-system indicators. One thing that stands out is how these near-term issues have overshadowed longer-term platform potential.
Forward-Looking Factors for Investors
Several elements will influence STXS ahead. Near-term items include the first commercial GenesisX installations in the U.S. and Europe, resolution of MAGiC supply constraints via a redundant in-house source, and progress on the regulatory milestone for the optional financing tranche. Recurring revenue recovery, conversion of the $1.9 million backlog, and whether adjusted operating expenses hold near the $8 million quarterly target also matter. Broader themes include pulsed field ablation adoption, endovascular robotics competition, and the path to cash-flow profitability. These remain forward-looking considerations, not investment advice. From what I see, monitoring these milestones closely will be important.
Enhancing Analysis with Tickeron Tools
In preparing this review, I used Tickeron’s AI Screener to compare STXS against sector peers and spot relevant performance patterns. The tool provides a straightforward way to filter and benchmark stocks efficiently. For investors seeking practical data-driven support in their own process, it serves as a useful addition to traditional research methods.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
STXS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for STXS turned positive on November 05, 2026. Looking at past instances where STXS's MACD turned positive, the stock continued to rise in 44 of 52 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STXS's RSI Oscillator exited the oversold zone, 24 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +8.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where STXS advanced for three days, in 152 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
STXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 50 cases where STXS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STXS as a result. In 79 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for STXS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. STXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.921) is normal, around the industry mean (4.964). P/E Ratio (-4.542) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (12.600) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a designer of robotic cardiology instrument navigation systems
Industry PharmaceuticalsOther
Advertisement